{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Number of participants with acute and late toxicity","groups":[{"description":"Dose Level 1: Patients administered 150mg Erlotinib daily and 200mg Celecoxib twice daily","id":"OG000","title":"Celecoxib 200mg"},{"description":"Dose Level 2: Patients administered 150mg Erlotinib daily and 400mg Celecoxib twice daily","id":"OG001","title":"Celecoxib 400mg"},{"description":"Dose Level 3: Patients administered 150mg Erlotinib daily and 600mg Celecoxib twice daily","id":"OG002","title":"Celecoxib 600mg"}],"paramType":"NUMBER","populationDescription":"Erlotinib and celecoxib were administered orally","reportingStatus":"POSTED","timeFrame":"30 DAYS","title":"Toxicity","type":"PRIMARY","unitOfMeasure":"participants"}